Denmark has the world’s second-best biotech policy environment
28 November 2018
To achieve biotech success, regulatory policy should be coordinated within government, and consistent stakeholder dialogue a formalised part of the process. Denmark hits the bull’s eye ranking second in the new Building the Bioeconomy report.
The Building the Bioeconomy series identify how successful biotechnology sectors can be built and sustained by looking at policy developments and overall performance in 33 of the major economies around the world.
Denmark takes the second spot in the newly released Building the Bioeconomy 2018.
Strong collaboration with universities
Life sciences in Denmark has its centre of gravity in Medicon Valley, one of the strongest life science clusters in Europe located at the gateway to Denmark and Sweden.
Four out of five companies in the Danish life science sector collaborated with a Danish university between 2014 and 2016 – in fact more than half of all Danish life science companies are located less than five kilometres from a university.
“Denmark was one of the first EU countries to put in place technology transfer legislation supporting university commercialisation of publicly funded research”
- Building the Bioeconomy 2018
You may also like: New genome research centre for precision medicine opens in Denmark
Digitisation and personalised medicine
In Denmark, the Government and Danish Regions have developed a National Strategy for Personalized Medicine 2017-2020 and mention digitalisation in the Growth Plan for Life Sciences as one of the opportunities to improve the growth conditions of the life science industry.
“Personalised medicine holds great potential to prevent and treat many lifestyle diseases. Denmark is renowned for its strong health research traditions and unique way of organising the health data of citizens in electronic registries, dating back decades – this one of the reasons why many life science companies choose to establish in Greater Copenhagen”.
- Claus Lønborg, CEO, Copenhagen Capacity
Highlights from the report
- In the category Rule of law, Denmark ranks 1 out of 113 countries
- Denmark has high regulatory standards for biopharmaceuticals, both EMA and national agency, Lægemiddelstyrelsen.
- By European standards the pricing and reimbursement environment for biopharmaceuticals is less stringent than other countries.
- Tax credits and deductions are available as R&D incentives. The R&D tax credit is up to 25% with a maximum cap of DKK 25 million.
- A number of funding measures is in place to help young and innovative biotechnology companies thrive.
Discover your opportunities in Greater Copenhagen
If you want to know more about life sciences and business opportunities in Greater Copenhagen, please contact Head of Life Sciences in Copenhagen Capacity, Niels Thun Andersen, via email email@example.com or phone 0045 30 62 74 27.